Virological Breakthrough: A Risk Factor for Loss to Followup in a Large Community-Based Cohort on Antiretroviral Therapy

Table 1

	All naïve adults with initial viral suppression: 𝑛=2959			Naïve adults with initial virological breakthrough: 𝑛=850
	Remain suppressed	Initial viral breakthrough		Resuppressed	Failed
Total number	2109	850	—	567 (67%)	283 (33%)	—
Female gender: 𝑛 (%)	1415 (67)	585 (68)	𝑃=.7733 *	386 (68)	200 (71)	𝑃=.7419 *
Age at treatment start: mean years (±SD)	35 (±8.7)	33 (±8.0)	𝑃=.0000 **	34 (±8.3)	32 (±7.5)	𝑃=.7591 **
WHO stage 1 or 2: 𝑛 (%)	611 (29)	228 (27)	𝑃=.5099 *	159 (28)	67 (24)	𝑃=.2981 *
WHO stage 3 or 4: 𝑛 (%)	1495 (71)	622 (73)	𝑃=.7068 *	406 (72)	216 (76)	𝑃=.5663 *
WHO stage unknown	3	0	—	0	0	—
Baseline CD4: median cells/mm^3 (IQR)	117 (62−168)	110 (50−163)	𝑃=.0003^#	110 (57−171)	83 (34−138)	𝑃=.0000^#
Baseline viral load: median copies/mL (IQR)	4.82 (4.39−5.26)	4.94 (4.51−5.30)	𝑃=.0002^#	4.86 (4.48−5.24)	5.07 (4.70−5.48)	𝑃=.0000^#

*Chi-squared.
** 𝑇-test.
^#Mann-Whitney 𝑈 test.